Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TABEA: Capecitabine + Taxane + Bevacizumab in MBC
NCT01200212Phase 3Terminated
- Sponsor
- GBG Forschungs
- Start
- Jul 2009
- Primary completion
- Oct 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by GBG Forschungs. Started Jul 2009; status: terminated.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01200212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01200212.